The healthcare titan Roche has secured a major acquisition of Poseida Therapeutics, with a share tender success of 66%. The news points to a clear win for both Roche and Poseida shareholders given the opportunities it opens in cell therapy. However, Roche's stock experience a slip following reports of side-effects from its weight-loss drug, including vomiting. The company nonetheless will push through with its plan to finalize the deal with the U.S. biopharma company. This comes amidst surges in the company's shares, especially after positive results from its obesity drug-trial were revealed. Despite a further 3.7% fall in Roche Holding stock last week, analysts anticipate a rebound in its 2022 highs. Roche recently secured a CE Mark for a breakthrough ovarian cancer diagnostic test and a strong buy rating upgrade. Directorship changes have been noted, with Roche CEO Vincent Roche selling shares worth $2.15 million. Meanwhile, the weight-loss market sees Roche as a challenge. The company's shares slipped following a modest 2024 outlook, and the side-effects of their obesity drug trial have raised concerns. Yet, Roche continues strong growth trend despite currency headwinds.
Roche Stocks News Analytics from Thu, 01 Feb 2024 08:00:00 GMT to Thu, 09 Jan 2025 15:26:00 GMT - Rating 6 - Innovation 2 - Information 8 - Rumor -5
